Regulatory BMS bags first approval for myeloma CELMoD Zenbexus PharmaphorumBristol Myers Squibb's CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma.HematologyRead full story pharminent August 14, 2026 (Last updated: August 21, 2026) Pharmaphorum Bristol Myers Squibb’s CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma. Hematology Read full story Post navigation Previous: PTC Therapeutics Acquires Sangamo’s Fabry Disease Gene TherapyNext: BMS Wins First FDA Approval for CELMoD Class With Zenbexus in Multiple Myeloma Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Trump nominates policy aide Overton to lead FDA pharminent August 19, 2026 Regulatory Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval pharminent August 17, 2026
